Sumitomo Mitsui Trust Group Inc. Sells 205,787 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP)

Sumitomo Mitsui Trust Group Inc. lessened its holdings in shares of CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 7.5% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,539,889 shares of the company's stock after selling 205,787 shares during the period. Sumitomo Mitsui Trust Group Inc. owned approximately 2.94% of CRISPR Therapeutics worth $86,432,000 at the end of the most recent quarter.

Several other institutional investors have also recently bought and sold shares of CRSP. Hedges Asset Management LLC boosted its position in CRISPR Therapeutics by 20.5% during the 1st quarter. Hedges Asset Management LLC now owns 29,350 shares of the company's stock worth $999,000 after acquiring an additional 5,000 shares during the last quarter. Tyche Wealth Partners LLC boosted its position in CRISPR Therapeutics by 10.2% during the 1st quarter. Tyche Wealth Partners LLC now owns 9,185 shares of the company's stock worth $313,000 after acquiring an additional 850 shares during the last quarter. Cambridge Investment Research Advisors Inc. boosted its position in CRISPR Therapeutics by 14.3% during the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 39,189 shares of the company's stock worth $1,334,000 after acquiring an additional 4,914 shares during the last quarter. Mason & Associates Inc acquired a new position in CRISPR Therapeutics during the 1st quarter worth approximately $201,000. Finally, Sowell Financial Services LLC boosted its position in CRISPR Therapeutics by 8.4% during the 1st quarter. Sowell Financial Services LLC now owns 11,554 shares of the company's stock worth $393,000 after acquiring an additional 900 shares during the last quarter. Institutional investors own 69.20% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on the company. Needham & Company LLC reiterated a "buy" rating and set a $81.00 price objective on shares of CRISPR Therapeutics in a research note on Thursday. JMP Securities reiterated a "market outperform" rating and set a $86.00 price objective on shares of CRISPR Therapeutics in a research note on Friday. Barclays dropped their price objective on CRISPR Therapeutics from $56.00 to $42.00 and set an "equal weight" rating on the stock in a research note on Friday, May 9th. Chardan Capital reiterated a "buy" rating and set a $82.00 price objective on shares of CRISPR Therapeutics in a research note on Thursday. Finally, Wall Street Zen upgraded CRISPR Therapeutics to a "sell" rating in a research note on Friday, May 16th. Two equities research analysts have rated the stock with a sell rating, six have given a hold rating and ten have given a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Hold" and an average price target of $71.75.

Insider Buying and Selling at CRISPR Therapeutics

In other CRISPR Therapeutics news, insider Naimish Patel sold 3,932 shares of the company's stock in a transaction on Thursday, May 29th. The stock was sold at an average price of $35.94, for a total value of $141,316.08. Following the transaction, the insider now directly owns 6,068 shares of the company's stock, valued at $218,083.92. This represents a 39.32% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Insiders own 4.10% of the company's stock.

CRISPR Therapeutics Trading Up 1.7%

CRSP opened at $47.49 on Monday. CRISPR Therapeutics AG has a 1-year low of $30.04 and a 1-year high of $63.68. The stock's fifty day simple moving average is $39.48 and its 200 day simple moving average is $40.47. The stock has a market cap of $4.10 billion, a PE ratio of -10.51 and a beta of 1.75.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last issued its quarterly earnings data on Tuesday, May 6th. The company reported ($1.58) EPS for the quarter, missing analysts' consensus estimates of ($1.27) by ($0.31). CRISPR Therapeutics had a negative net margin of 1,023.64% and a negative return on equity of 20.08%. During the same period last year, the business earned ($1.43) earnings per share. The business's quarterly revenue was up 71.6% compared to the same quarter last year. Equities analysts forecast that CRISPR Therapeutics AG will post -5.16 earnings per share for the current year.

CRISPR Therapeutics Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.